Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
114.64
+0.70 (0.61%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for LGND stock have an average target of 145, with a low estimate of 135 and a high estimate of 160. The average target predicts an increase of 26.48% from the current stock price of 114.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LGND stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +39.57% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +24.74% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +22.12% | Nov 12, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $110 → $135 | Strong Buy | Maintains | $110 → $135 | +17.76% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
166.59M
from 131.31M
Increased by 26.86%
Revenue Next Year
188.51M
from 166.59M
Increased by 13.16%
EPS This Year
5.70
from 2.94
Increased by 94.29%
EPS Next Year
6.15
from 5.70
Increased by 7.82%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 173.1M | 204.8M | 246.8M | |||
| Avg | 166.6M | 188.5M | 213.5M | |||
| Low | 158.5M | 165.4M | 174.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 31.8% | 22.9% | 30.9% | |||
| Avg | 26.9% | 13.2% | 13.3% | |||
| Low | 20.7% | -0.7% | -7.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.08 | 7.79 | 9.50 | |
| Avg | 5.70 | 6.15 | 6.70 | |
| Low | 5.22 | 4.67 | 4.51 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 107.1% | 36.6% | 54.5% | |
| Avg | 94.3% | 7.8% | 8.9% | |
| Low | 77.9% | -18.1% | -26.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.